Monoclonal antibodies: From structure to therapeutic application

Pharmaceutical Biotechnology: Fundamentals and Applications, Third Edition

Volumn , Issue , 2016, Pages 309-337

  Anand, Banmeet ^a   Deng, Rong ^a   Theil, Frank Peter ^a   Li, Jing ^a   Jumbe, Shasha ^a   Gelzleichter, Thomas ^a   Fielder, Paul ^a   Joshi, Amita ^a   Kenkare Mitra, Saraswati ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903803474     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (124)

1. Alefacept (2003). Alefacept (Amevive) (prescribing information). Cambridge, MA: Biogen Inc.
2. Avastin (2004). Avastin (Bevacizumab) (prescribing information). South San Francisco, CA: Genentech, Inc.
3. Baert F, Noman M, Vermeire S, et al. (2003). Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348(7):601-8.
4. Bauer RJ, Dedrick RL, White ML, et al. (1999). Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27(4):397-420.
5. Baxter LT, Zhu H, Mackensen DG, et al. (1995). Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 55(20):4611-22.
6. Baxter LT, Zhu H, Mackensen DG, Jain RK. (1994). Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54(6):1517-28.
7. Bazin-Redureau MI, Renard CB, Scherrmann JM. (1997). Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat. J Pharm Pharmacol 49(3):277-81.
8. Berger MA, Masters GR, Singleton J, et al. (2005). Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776.1 in a murine model of human ovarian cancer. Cancer Biother Radiopharm 20(6):589-602.
9. Bexxar (2003). Bexxar (Tositumomab) (prescribing information). Seattle, WA: Corixa Corp and Philadelphia, PA:GlaxoSmithKline.
10. Boxenbaum H, Battle M. (1995). Effective half-life in clinical pharmacology. J Clin Pharmacol 35(8):763-6.
11. Brambell F, Hemmings W, Morris I. (1964). A theoretical model of gamma-globulin catabolism. Nature 203:1352-1355.
12. Bugelski PJ, Herzyk DJ, Rehm S, et al. (2000). Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice:characterization of the model and safety studies. Hum Exp Toxicol 19(4):230-43.
13. Bunescu A, Seideman P, Lenkei R, et al. (2004). Enhanced Fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J Rheumatol 31(12):2347-55.
14. Cartron G, Watier H, Golay J, Solal-Celigny P. (2004). From the bench to the bedside: ways to improve rituximab efficacy. Blood 104(9):2635-42.
15. Clarke J, Leach W, Pippig S, et al. (2004). Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody. Regul Toxicol Pharmacol 40(3):219-26.
16. Coffey GP, Fox JA, Pippig S, et al. (2005). Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos 33(5):623-9.
17. Cohenuram M, Saif MW. (2007). Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18(1):7-15.
18. Cornillie F, Shealy D, D'Haens G, et al. (2001). Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 15(4):463-73.
19. Dall'Ozzo S, Tartas S, Paintaud G, et al. (2004). Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64(13):4664-9.
20. Danilov SM, Gavrilyuk VD, Franke FE, et al. (2001). Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. Am J Physiol Lung Cell Mol Physiol 280(6):L1335-47.
21. Dedrick RL. (1973). Animal scale-up. J Pharmacokinet Biopharm 1(5):435-61.
22. Dedrick RL, Walicke P, Garovoy M. (2002). Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl Immunol 9(2-4):181-6.
23. den Broeder A, van de Putte L, Rau R, et al. (2002). A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29(11):2288-98.
24. Dickinson BL, Badizadegan K, Wu Z, et al. (1999). Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 104(7):903-11.
25. Dowell JA, Korth-Bradley J, Liu H, et al. (2001). Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 41(11):1206-14.
26. Druet P, Bariety J, Laliberte F, et al. (1978). Distribution of heterologous antiperoxidase antibodies and their fragments in the superficial renal cortex of normal Wistar-Munich rat: an ultrastructural study. Lab Invest 39(6):623-31.
27. Duconge J Castillo R, Crombet T, et al. (2004). Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody. Eur J Pharm Sci 21(2-3):261-70.
28. Erbitux (2004). Erbitux (Cetuximab) (prescribing information). Branchburg, NJ: Imclone Systems Incorporated and Princeton, NJ: Bristol-Myers Squibb Company.
29. Ferl GZ, Wu AM, DiStefano JJ. III. (2005). A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 33(11):1640-52.
30. Ghetie V, Hubbard JG, Kim JK, et al. (1996). Abnormally short serum half-lives of IgG in beta 2-microglobulindeficient mice. Eur J Immunol 26(3):690-6.
31. Gillies SD, Lan Y, Lo KM, et al. (1999). Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors. Cancer Res 59(9):2159-66.
32. Gillies SD, Lo KM, Burger C, et al. (2002). Improved circulating half-life and efficacy of an antibodyinterleukin 2 immunocytokine based on reduced intracellular proteolysis. Clin Cancer Res 8(1):210-16.
33. Goldsby RA, Kindt TJ, Osborine BA. (1999). Immunoglobulins: Structure and Function Kuby Immunology. 4th ed. New York: W.H. Freeman and Company.
34. Gottlieb AB, Miller B, Lowe N, et al. (2003). Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis. J Cutan Med Surg 7(3):198-207.
35. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. (2007). A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 63(5):548-61.
36. Herceptin (2006). Herceptin (Trastuzumab) (prescribing information). South San Francisco, CA, USA.
37. Hervey PS, Keam SJ. (2006). Abatacept. BioDrugs 20(1):53-61; discussion 62.
38. Hinton PR, Xiong JM, Johlfs MG, et al. (2006). An engineered human IgG1 antibody with longer serum half-life. J Immunol 176(1):346-56.
39. Hooks MA, Wade CS, Millikan WJ, Jr. (1991). Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 11(1):26-37.
40. Huang L, Biolsi S, Bales KR, Kuchibhotla U. (2006). Impact of variable domain glycosylation on antibody clearance:an LC/MS characterization. Anal Biochem 349(2):197-207.
41. Humira (2007). Humira (Adalimumab) (prescribing information). Chicago, IL, USA.
42. ICH (1997a). ICH Harmonized Tripartite Guideline S6:Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals.
43. ICH (1997b). ICH Harmonized Tripartite Guideline M3:Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals.
44. Jolling K, Perez Ruixo JJ, Hemeryck A, et al. (2005). Mixedeffects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci 24(5):465-75.
45. Joshi A, Bauer R, Kuebler P, et al. (2006). An overview of the pharmacokinetics and pharmacodynamics of efalizumab:a monoclonal antibody approved for use in psoriasis. J Clin Pharmacol 46(1):10-20.
46. Junghans RP. (1997). Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 16(1):29-57.
47. Junghans RP, Anderson CL. (1996). The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93(11):5512-16.
48. Kairemo KJ, Lappalainen AK, Kaapa E, et al. (2001). In vivo detection of intervertebral disk injury using a radiolabeled monoclonal antibody against keratan sulfate. J Nucl Med 42(3):476-82.
49. Kelley SK, Gelzleichter T, Xie D, et al. (2006). Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 148(8):1116-23.
50. Kleiman NS, Raizner AE, Jordan R, et al. (1995). Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 26(7):1665-71.
51. Kohler G, Milstein C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495-7.
52. Kolar GR, Capra JD. (2003). In: Paul WE, ed. Immunoglobulins:Structure and Function Fundamental Immunology. 5th ed. Philadephia, PA: LippincottWilliams &Wilkins.
53. Koon HB, Severy P, Hagg DS, et al. (2006). Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. Leuk Res 30(2):190-203.
54. Kovarik JM, Nashan B, Neuhaus P, et al. (2001). A population pharmacokinetic screen to identify demographic- clinical covariates of basiliximab in liver transplantation. Clin Pharmacol Ther 69(4):201-9.
55. Krueger JG. (2002). The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46(1):1-23; quiz 23-6.
56. Kuus-Reichel K, Grauer LS, Karavodin LM, et al. (1994).Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 1(4):365-72.
57. Lee H, Kimko HC, Rogge M, et al. (2003). Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73(4):348-65.
58. Lin YS, Nguyen C, Mendoza JL, et al. (1999). Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288(1):371-8.
59. Lobo ED, Hansen RJ, Balthasar JP. (2004). Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93(11):2645-68.
60. Looney RJ, Anolik JH, Campbell D, et al. (2004). B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50(8):2580-9.
61. Lucentis (2006). Lucentis (Ranibizumab) (prescribing information). South San Francisco, CA, USA.
62. Mahmood I. (2005a). Interspecies Pharmacokinetics Scaling. Rockville: Pine House Publishers.
63. Mahmood I. (2005b). Prediction of concentration-time profiles in humans. In: Interspecies Pharmacokinetics Scaling. Rockville: Pine House Publishers:219-41.
64. Mahmood I, Green MD. (2005). Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 44(4):331-47.
65. Martin-Jimenez T. Riviere JE. (2002). Mixed-effects modeling of the interspecies pharmacokinetic scaling of oxytetracycline. J Pharm Sci 91(2):331-41.
66. McClurkan MB, Valentine JL, Arnold L, Owens SM. (1993). Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats. J Pharmacol Exp Ther 266(3):1439-45.
67. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16(8):2825-33.
68. Medesan C, Matesoi D, Radu C, et al. (1997). Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol 158(5):2211-17.
69. Meibohm B, Derendorf H. (2002). Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci 91(1):18-31.
70. Meijer RT, Koopmans RP, ten Berge IJ, Schellekens PT. (2002). Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen. J Pharmacol Exp Ther 300(1):346-53.
71. Meredith PA, Elliott HL, Donnelly R, Reid JL. (1991). Doseresponse clarification in early drug development. J Hypertens Suppl 9(6):S356-7.
72. Morris EC, Rebello P, Thomson KJ, et al. (2003). Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations:relevance for early adoptive immunotherapy and infectious complications. Blood 102(1):404-6.
73. Mortensen DL, Walicke PA, Wang X, et al. (2005). Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol 45(3):286-98.
74. Mould DR, Davis CB, Minthorn EA, et al. (1999). A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clin Pharmacol Ther 66(3):246-57.
75. Mould DR, Sweeney KR. (2007). The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 10(1):84-96.
76. Nakakura EK, McCabe SM, Zheng B, et al. (1993). Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion. Transplantation 55(2):412-17.
77. Nestorov I, Zitnik R, Ludden T. (2004). Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. J Pharmacokinet Pharmacodyn 31(6):463-90.
78. Newkirk MM, Novick J, Stevenson MM, et al. (1996). Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice. Clin Exp Immunol 106(2):259-64.
79. Ng CM, Joshi A, Dedrick RL, et al. (2005). Pharmacokineticpharmacodynamic- efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res 22(7):1088-100.
80. Ng CM, Stefanich E, Anand BS, et al. (2006). Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 23(1):95-103.
81. Norman DJ, Chatenoud L, Cohen D, et al. (1993). Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. Transplant Proc 25(2 Suppl 1):89-92.
82. Ober RJ, Radu CG, Ghetie V, Ward ES. (2001). Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13(12):1551-9.
83. Papp K, Bissonnette R, Krueger JG., et al. (2001). The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 45(5):665-74.
84. Petkova SB, Akilesh S, Sproule TJ, et al. (2006). Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18(12):1759-69.
85. Presta LG. (2002). Engineering antibodies for therapy. Curr Pharm Biotechnol 3(3):237-56.
86. Presta LG, Shields RL, Namenuk AK, et al. (2002). Engineering therapeutic antibodies for improved function. Biochem Soc Trans 30(4):487-90.
87. Raptiva (2004). Raptiva (Efalizumab) (prescribing information). South San Francisco, CA: Genentech, Inc.
88. Remicade (2006). Remicade (Infliximab) (prescribing information). Malvenr, PA: Centocor Inc.
89. Rituxan (2006). Rituxan (Rituximab) (prescribing information). South San Francisco, CA, USA: Genentech Inc. and Cambridge, MA: Biogen Inc.
90. Roopenian DC, Christianson GJ, Sproule TJ, et al. (2003). The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fccoupled drugs. J Immunol 170(7):3528-33.
91. Roskos LK, Davis CG, Schwab GM. (2004). The clinical pharmacology of therapeutic monoclonal antibodies. Drug Develop Res 61(3):108-20.
92. Schror K, Weber AA. (2003). Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 15(2):71-80.
93. Sheiner L, Wakefield, J. (1999). Population modelling in drug development. Stat Methods Med Res 8(3):183-93.
94. Sheiner LB. (1997). Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61(3):275-91.
95. Shields RL, Namenuk AK, Hong K, et al. (2001). High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276(9):6591-604.
96. Simister NE, Mostov KE. (1989a). Cloning and expression of the neonatal rat intestinal Fc receptor, a major histocompatibility complex class I antigen homolog. Cold Spring Harb Symp Quant Biol 54(Pt 1):571-80.
97. Simister NE, Mostov KE. (1989b). An Fc receptor structurally related to MHC class I antigens. Nature 337(6203):184-7.
98. Simulect (2005). Simulect (Basiliximab) (prescribing information). East Hanover, NJ, USA.
99. Spiekermann GM, Finn PW, Ward ES, et al. (2002). Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med 196(3):303-10.
100. Straughn AB. (2006). Limitations of noncompartmental pharmacokinetic analysis of biotech drugs. In: Meibohm B, ed. Pharmacokinetics and Pharmacodynamics of Biotech Drugs. Weinheim:Wiley, 181-8.
101. Subramanian GM, Cronin PW, Poley G, et al. (2005). A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis 41(1):12-20.
102. Sun YN, Lu JF, Joshi A, et al. (2005). Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol 45(4):468-76.
103. Synagis (2004). Synagis (Palivizumab) (prescribing information). Gaithersburg, MD: MedImmune, Inc. and Columbus, OH: Abbott Laboratories Inc.
104. Tabrizi MA, Tseng CM, Roskos LK. (2006). Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 11(1-2):81-8.
105. Tang H, Mayersohn M. (2005). Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection. Drug Metab Dispos 33(9):1288-93.
106. Tang L, Persky AM, Hochhaus G, Meibohm B. (2004). Pharmacokinetic aspects of biotechnology products. J Pharma Sci 93(9): 2184-204.
107. Ternant D, Paintaud G. (2005). Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 5(Suppl 1):S37-47.
108. Tokuda Y, Watanabe T, Omuro Y, et al. (1999). Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 81(8):1419-25.
109. Tysabri (2006). Tysabri (Natalizumab) (prescribing information). San Diego, CA: Elan Pharmaceuticals Inc. and Cambridge, MA: Biogen Idec Inc.
110. Umana P, Jean-Mairet J, Moudry R, et al. (1999). Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17(2):176-80.
111. Vaccaro C, Bawdon R, Wanjie S, et al. (2006). Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci USA 103(49):18709-14.
112. Vaishnaw AK, TenHoor CN. (2002). Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn 29(5-6):415-26.
113. Wang W, Singh S, Zeng DL, et al. (2007). Antibody structure, instability, and formulation. J Pharm Sci 96(1):1-26.
114. Watanabe N, Kuriyama H, Sone H, et al. (1988). Continuous internalization of tumor necrosis factor receptors in a human myosarcoma cell line. J Biol Chem 263(21):10262-6.
115. Weiner LM. (2006). Fully human therapeutic monoclonal antibodies. J Immunother 29(1):1-9.
116. Weisman MH, Moreland LW, Furst DE, et al. (2003). Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25(6):1700-21.
117. Werther WA, Gonzalez TN, O'Connor SJ, et al. (1996). Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 157(11):4986-95.
118. Wurster U, Haas J. (1994). Passage of intravenous immunoglobulin and interaction with the CNS. J Neurol Neurosurg Psychiatry 57(Suppl):21-5.
119. Xolair (2006). Xolair (Omalizumab) (prescribing information). South San Francisco, CA, USA: Genentech Inc. and East Hanover, NJ, USA: Novartis.
120. Yim D S, Zhou H, Buckwalter M, et al. (2005). Population pharmacokinetic analysis and simulation of the timeconcentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 45(3):246-56.
121. Zenapax (2005). Zenapax (Daclizumab) (prescribing information). Nutley, NJ, USA.
122. Zhou H. (2005). Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 45(5):490-7.
123. Zhou H, Mayer PR, Wajdula J, Fatenejad S. (2004). Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol 44(11):1235-43.
124. Zia-Amirhosseini, P, Minthorn E, Benincosa LJ, et al. (1999). Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther 291(3):1060-7.